 Braxia Scientific Corp. CSE:BRAX OTC:BRAXF, a Toronto-based psychedelics company, is launching a randomized clinical trial using psilocybin for adults with treatment-resistant depression. A number of organizations and for-profit companies in the psychedelics space are looking at the clinical applications of psilocybin in the treatment of depression, including the Usona Institute and Compass Pathways NASDAQ:CMPS. 